Evidence suggesting an initial half dose of the vaccine being developed by drugs firm AstraZeneca and the University of Oxford is more effective than a full dose is counterintuitive, and even took the researchers by surprise. Why would less be better than more when it comes to triggering an immune response? Andrew Pollard, the director